KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Gross Margin: 2009-2025

Historic Gross Margin for Rigel Pharmaceuticals (RIGL) over the last 12 years, with Sep 2025 value amounting to 93.16%.

  • Rigel Pharmaceuticals' Gross Margin rose 767.00% to 93.16% in Q3 2025 from the same period last year, while for Sep 2025 it was 93.10%, marking a year-over-year increase of 367.00%. This contributed to the annual value of 89.60% for FY2024, which is 432.00% down from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' Gross Margin is 93.16%, which was down 2.53% from 95.57% recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Gross Margin registered a high of 99.61% during Q1 2021, and its lowest value of 85.49% during Q3 2024.
  • Moreover, its 3-year median value for Gross Margin was 93.14% (2024), whereas its average is 92.60%.
  • In the last 5 years, Rigel Pharmaceuticals' Gross Margin slumped by 1,000bps in 2024 and then soared by 767bps in 2025.
  • Quarterly analysis of 5 years shows Rigel Pharmaceuticals' Gross Margin stood at 97.61% in 2021, then skyrocketed by 172bps to 99.33% in 2022, then slumped by 992bps to 89.41% in 2023, then skyrocketed by 54bps to 89.95% in 2024, then surged by 767bps to 93.16% in 2025.
  • Its last three reported values are 93.16% in Q3 2025, 95.57% for Q2 2025, and 91.73% during Q1 2025.